Shots:
- Regeneron has submitted a request to the US FDA seeking EUA for its REGN-COV2 investigational Ab regimen to treat COVID-19. If EUA is granted, the US govt. has committed to making REGN-COV2 available in the US at no cost and would be responsible for its distribution
- The company reported that there are doses available for ~50,000 patients and expects to have doses available for 300,000 patients in total within the next few months
- REGN-COV2 is a combination of two mAbs, REGN10933 & REGN10987, designed to block the infectivity of SARS-CoV-2. The company reported that a single 8g dose of REGN-COV2 was given to President Donald Trump following a compassionate-use request from doctors as part of a treatment regimen
Click here to read full press release/ article | Ref: Eyewire | Image: Times Union
The post Regeneron Seeks the US FDA’s EUA for REGN-COV2 Antibody Combination to Treat COVID-19 first appeared on PharmaShots.
